Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Landscape and selection of vaccine epitopes in SARS-CoV-2

Fig. 3

Landscape of SARS-CoV-2 MHC ligands. A,B Selection criteria for A HLA-I and B HLA-II SARS-CoV-2 HLA ligand candidates. Scatterplot (bottom) shows predicted (x-axis) versus IEDB (y-axis) binding affinity, with horizontal line representing 500 nM IEDB binding affinity and vertical line representing corresponding predicted binding affinity for 90% specificity in binding prediction. Histogram (top) shows all predicted SARS-CoV-2 HLA ligand candidates. Scatterplot in B shows subsampled points from HLA-DRB1 alleles (< 50 points per allele) to allow for increased visibility of points. C Landscape of predicted HLA ligands, showing HLA-I (red) and HLA-II (blue) ligands with U.S. population coverage > 50% (top), and LOESS fitted curve (span = 0.1) for HLA-I/II ligands by location along the SARS-CoV2 proteome (color tracks). The predicted binding affinity of HLA ligand peptides to murine H2-b/d alleles is represented with point shading. D Summary of murine/human MHC ligand overlap. E Distribution of population frequencies among predicted HLA-I and HLA-II ligands

Back to article page